Using genetics to investigate the association between lanosterol and cataract

Area of Science:

• Ophthalmology
• Genetics
• Pharmacology

Background:

• Cataract is a leading cause of global blindness, with surgery as the primary treatment.
• Non-surgical treatments are needed, especially in developing countries.
• Topical lanosterol has been investigated for cataract treatment, but results are inconclusive.

Purpose of the Study:

• To investigate genetic associations between lanosterol and cataract risk.
• To explore lanosterol's potential as a non-surgical cataract treatment option.
• To combine genetic evidence with existing research on lanosterol and cataract.

Main Methods:

• A genome-wide association study (GWAS) was conducted using UK Biobank data from 45,449 cataract cases (ages 40-69).
• Focused on genetic variants in the lanosterol synthase gene region.
• Analyzed genetic associations of phytosterol-to-lanosterol ratios and performed a genetic risk score analysis for lanosterol in the cholesterol synthesis pathway.

Main Results:

• No significant single nucleotide polymorphism (SNP) associations with cataract were found in the lanosterol synthase gene region.
• Genetic associations of phytosterol-to-lanosterol ratios did not support lanosterol's protective effects against cataract.
• No statistically significant association was observed between a lanosterol genetic risk score and cataract outcomes (OR = 1.002, p = 0.568).

Conclusions:

• This study found no genetic evidence supporting a link between lanosterol and cataract risk.
• The results do not support the use of lanosterol for treating cataracts.
• Further research may be necessary to evaluate lanosterol's effect on specific cataract subtypes.